labetalol has been researched along with Bright Disease in 2 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martínez, SE | 1 |
| García Contreras, ML | 1 |
| Manzella, DJ | 1 |
| Brugnolo, MR | 1 |
| Raab, LA | 1 |
| Dobarro, M | 1 |
| Palla, R | 1 |
| Bionda, A | 1 |
| Carmassi, F | 1 |
| Giusti, R | 1 |
| Marchitiello, M | 1 |
2 other studies available for labetalol and Bright Disease
| Article | Year |
|---|---|
[Reversible posterior leukoencephalopathy syndrome].
Topics: Antihypertensive Agents; Female; Glomerulonephritis; Humans; Labetalol; Posterior Leukoencephalopath | 2017 |
[Effect of treatment with labetalol on renal function in arterial hypertension secondary to parenchymal nephropathy and in essential arterial hypertension].
Topics: Adult; Chronic Disease; Ethanolamines; Glomerulonephritis; Humans; Hypertension; Hypertension, Renal | 1980 |